{"id":"cytokine-induced-killer-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Cytokine release syndrome"}]},"_chembl":{"chemblId":"CHEMBL5315108","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CIK cells are generated by culturing patient-derived peripheral blood mononuclear cells with interferon-gamma, anti-CD3 antibodies, and interleukin-2 to expand a population of CD3+CD56+ cells. These cells combine the tumor-targeting specificity of T cells with the broad cytotoxic capability of natural killer cells, enabling recognition of tumor-associated antigens and direct killing of malignant cells.","oneSentence":"Cytokine-Induced Killer (CIK) cells are ex vivo expanded autologous T lymphocytes that recognize and kill tumor cells through both MHC-restricted and non-restricted pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:19.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (phase 3 development)"},{"name":"Hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06321484","phase":"PHASE1","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-09","conditions":"Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer","enrollment":18},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT06389305","phase":"NA","title":"CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-05-27","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia","enrollment":213},{"nctId":"NCT05580601","phase":"PHASE1, PHASE2","title":"Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-05-05","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07011004","phase":"PHASE1","title":"A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT06318871","phase":"EARLY_PHASE1","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-28","conditions":"Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma","enrollment":10},{"nctId":"NCT07343791","phase":"EARLY_PHASE1","title":"Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","status":"RECRUITING","sponsor":"JIANG LONGWEI","startDate":"2025-11-19","conditions":"DC-CIK Treatment, Regorafenib, Colorectal Cancer","enrollment":14},{"nctId":"NCT06138587","phase":"PHASE1","title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-24","conditions":"Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid","enrollment":15},{"nctId":"NCT02782546","phase":"PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-30","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT05336409","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies","status":"TERMINATED","sponsor":"Century Therapeutics, Inc.","startDate":"2023-01-24","conditions":"R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT07274449","phase":"PHASE1, PHASE2","title":"Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-05-08","conditions":"Advanced Solid Cancers","enrollment":6},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT07260058","phase":"PHASE1, PHASE2","title":"Immune Cell Therapy for Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","startDate":"2025-12-01","conditions":"Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)","enrollment":48},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT03068819","phase":"PHASE1, PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-10-23","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT05629546","phase":"PHASE1","title":"Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-06","conditions":"Advanced Melanoma, Metastatic Melanoma","enrollment":33},{"nctId":"NCT04836728","phase":"PHASE2","title":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-31","conditions":"Non-small Cell Lung Cancer Metastatic, First-line Treatment","enrollment":156},{"nctId":"NCT01868490","phase":"PHASE1, PHASE2","title":"The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells","status":"ENROLLING_BY_INVITATION","sponsor":"Siriraj Hospital","startDate":"2009-04-17","conditions":"Cholangiocarcinoma, Neuroblastoma","enrollment":20},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT04634435","phase":"PHASE1","title":"Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2021-10-21","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT06684899","phase":"","title":"Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-11","conditions":"Glioblastoma, Cytokine-Induced Killer Cells","enrollment":40},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":"Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion","enrollment":100},{"nctId":"NCT01898663","phase":"PHASE1, PHASE2","title":"DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-06","conditions":"High-risk Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT05268172","phase":"PHASE1","title":"IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites","status":"RECRUITING","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":"Pleural Effusion, Malignant","enrollment":40},{"nctId":"NCT05869279","phase":"PHASE1, PHASE2","title":"Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","startDate":"2023-12-01","conditions":"B-cell NHL, CLL","enrollment":29},{"nctId":"NCT04282044","phase":"PHASE1","title":"Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"BioEclipse Therapeutics","startDate":"2021-01-08","conditions":"Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT03757858","phase":"PHASE1, PHASE2","title":"Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2018-03-01","conditions":"Cancer, Abdominal Cancer, Pelvic Cancer","enrollment":40},{"nctId":"NCT03393858","phase":"PHASE1, PHASE2","title":"Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma","status":"TERMINATED","sponsor":"Capital Medical University","startDate":"2017-12-01","conditions":"Cancer, Mesothelioma, Malignant","enrollment":10},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT01884168","phase":"","title":"Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-03","conditions":"Malignant Tumor","enrollment":30},{"nctId":"NCT03190811","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-09","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT03360630","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-11-01","conditions":"Lung Cancer, Neoplasms","enrollment":60},{"nctId":"NCT01898793","phase":"PHASE1, PHASE2","title":"Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2014-08-11","conditions":"Leukemia, Myeloid, Acute","enrollment":89},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT00699816","phase":"PHASE3","title":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2008-07","conditions":"Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT03983967","phase":"PHASE1, PHASE2","title":"Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2019-01-24","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT02856815","phase":"PHASE2","title":"Safety and Efficacy of \"Immuncell-LC\" in TACE Therapy","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2018-05-28","conditions":"Carcinoma, Hepatocellular","enrollment":76},{"nctId":"NCT05256277","phase":"PHASE1","title":"NK Cell Therapy for AML","status":"TERMINATED","sponsor":"Zhejiang University","startDate":"2021-12-28","conditions":"AML","enrollment":3},{"nctId":"NCT03389035","phase":"PHASE1, PHASE2","title":"Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT","status":"COMPLETED","sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","startDate":"2017-12-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse","enrollment":21},{"nctId":"NCT04802070","phase":"PHASE1","title":"Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.","status":"COMPLETED","sponsor":"Prof. Franca Fagioli","startDate":"2021-01-11","conditions":"Sarcoma","enrollment":7},{"nctId":"NCT04354025","phase":"PHASE2","title":"Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2023-06-30","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04214717","phase":"NA","title":"Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Yantai Yuhuangding Hospital","startDate":"2019-12-31","conditions":"Solid Tumor","enrollment":60},{"nctId":"NCT05676190","phase":"NA","title":"Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer","status":"RECRUITING","sponsor":"ShiCang Yu","startDate":"2023-01-09","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT02752243","phase":"PHASE1, PHASE2","title":"CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.","status":"UNKNOWN","sponsor":"Peter Bader","startDate":"2016-03","conditions":"Myelodysplastic Syndromes, Acute Leukemia","enrollment":32},{"nctId":"NCT04893915","phase":"PHASE2","title":"Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2022-06-30","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT05246228","phase":"","title":"Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy","status":"UNKNOWN","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2022-03-01","conditions":"Squamous Cell Carcinoma of the Skin","enrollment":42},{"nctId":"NCT05108077","phase":"PHASE1, PHASE2","title":"Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells","status":"UNKNOWN","sponsor":"Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","startDate":"2022-03-01","conditions":"Bladder Cancer, Renal Cancer","enrollment":20},{"nctId":"NCT03821519","phase":"PHASE1, PHASE2","title":"Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant","status":"UNKNOWN","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2019-01-13","conditions":"Relapsed Hematologic Malignancy","enrollment":20},{"nctId":"NCT05020119","phase":"PHASE1","title":"Neoantigen-expanded Autologous Immune Cell Therapy","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-04-09","conditions":"Advanced Solid Tumor","enrollment":9},{"nctId":"NCT01787474","phase":"PHASE1","title":"Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-19","conditions":"Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT02621333","phase":"PHASE2","title":"Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2015-10","conditions":"Lung Adenocarcinoma","enrollment":280},{"nctId":"NCT03329664","phase":"PHASE1, PHASE2","title":"Autologous Killer Cell Therapy in Colon Cancer Patients","status":"UNKNOWN","sponsor":"Sabz Biomedicals","startDate":"2020-02-09","conditions":"Colon Cancer Stage IV","enrollment":20},{"nctId":"NCT03146637","phase":"PHASE2","title":"Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","startDate":"2017-05-01","conditions":"Advanced Liver Cancer","enrollment":80},{"nctId":"NCT03782363","phase":"PHASE1","title":"Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.","status":"WITHDRAWN","sponsor":"Italian Sarcoma Group","startDate":"2020-12-18","conditions":"Sarcoma","enrollment":""},{"nctId":"NCT03524274","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-05","conditions":"Advanced Colorectal Cancer","enrollment":""},{"nctId":"NCT03509298","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-12","conditions":"Advanced Pancreatic Cancer","enrollment":""},{"nctId":"NCT03501056","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-03-27","conditions":"Advanced Lung Cancer","enrollment":""},{"nctId":"NCT03540199","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-10","conditions":"Advanced Kidney Cancer","enrollment":""},{"nctId":"NCT03484962","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-03-25","conditions":"Advanced Liver Cancer","enrollment":""},{"nctId":"NCT03524261","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2019-05-20","conditions":"Advanced Breast Cancer","enrollment":""},{"nctId":"NCT03554395","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-05","conditions":"Advanced Gastric Cancer","enrollment":""},{"nctId":"NCT04476641","phase":"PHASE2","title":"A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-05-06","conditions":"Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer","enrollment":686},{"nctId":"NCT03987867","phase":"PHASE1","title":"Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer, First-line Treatment","enrollment":30},{"nctId":"NCT03987698","phase":"PHASE2","title":"Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":90},{"nctId":"NCT03983759","phase":"PHASE2","title":"Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-06-20","conditions":"Small Cell Lung Cancer, Extensive Disease, Adoptive Cellular Immunotherapy","enrollment":40},{"nctId":"NCT03002831","phase":"PHASE2","title":"Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2016-11","conditions":"Advanced Cancer","enrollment":13},{"nctId":"NCT04292769","phase":"PHASE3","title":"Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors","status":"UNKNOWN","sponsor":"Li Yu","startDate":"2020-01-21","conditions":"Malignant Neoplasm","enrollment":200},{"nctId":"NCT02585908","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of γδ T Cell Against Gastric Cancer","status":"UNKNOWN","sponsor":"Beijing Doing Biomedical Co., Ltd.","startDate":"2019-12","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT01631357","phase":"PHASE2, PHASE3","title":"Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT01691664","phase":"NA","title":"Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Cancer","enrollment":40},{"nctId":"NCT02425748","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2017-06-08","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT01392989","phase":"PHASE2","title":"Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders","status":"COMPLETED","sponsor":"Everett Meyer","startDate":"2011-03","conditions":"Neural Tube Defects, Anemia, Leukemia, Myeloid","enrollment":44},{"nctId":"NCT03815630","phase":"EARLY_PHASE1","title":"A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Allife Medical Science and Technology Co., Ltd.","startDate":"2019-02-01","conditions":"Solid Tumor","enrollment":100},{"nctId":"NCT01186809","phase":"PHASE2","title":"Cytokine Induced Killer (CIK) Cells In Leukemia Patients","status":"COMPLETED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2009-07","conditions":"Hematologic Malignancies","enrollment":74},{"nctId":"NCT03736330","phase":"PHASE2","title":"A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-09-08","conditions":"Renal Cancer Metastatic","enrollment":24},{"nctId":"NCT01783951","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-02-01","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT01894373","phase":"PHASE1, PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2015-06","conditions":"Psoriasis, Adoptive Immunotherapy","enrollment":10},{"nctId":"NCT01781520","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-06-01","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT03282435","phase":"PHASE1","title":"Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody","status":"UNKNOWN","sponsor":"Dalian University","startDate":"2018-01","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT02482454","phase":"PHASE2, PHASE3","title":"Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2012-07","conditions":"Cholangiocarcinoma","enrollment":50},{"nctId":"NCT03220984","phase":"PHASE2","title":"The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2017-03-16","conditions":"Metastatic Colorectal Cancer","enrollment":28},{"nctId":"NCT03158480","phase":"NA","title":"Safety and Efficacy of Immune Therapy for Condyloma","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2017-06-25","conditions":"Condylomata Acuminata","enrollment":80},{"nctId":"NCT02568748","phase":"PHASE3","title":"Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2015-10","conditions":"Liver Cancer","enrollment":20},{"nctId":"NCT03124498","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA","status":"UNKNOWN","sponsor":"Chuan An Biotechnology Co., Ltd.","startDate":"2017-11","conditions":"Hepatocellular Carcinoma","enrollment":55},{"nctId":"NCT03084809","phase":"PHASE4","title":"Chemotherapy Combined With CIK Treating Colon Cancer","status":"COMPLETED","sponsor":"China Meitan General Hospital","startDate":"2012-05-06","conditions":"Colorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications","enrollment":46},{"nctId":"NCT00394381","phase":"PHASE1, PHASE2","title":"Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, High Grade","enrollment":17},{"nctId":"NCT00815321","phase":"PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2008-12","conditions":"Chronic Myeloid Leukemia","enrollment":11},{"nctId":"NCT00460694","phase":"PHASE1, PHASE2","title":"Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia","enrollment":24},{"nctId":"NCT03047525","phase":"PHASE1, PHASE2","title":"Study of DC-CTL Combined With CIK for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Xiaoyi Huang","startDate":"2017-02-20","conditions":"Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT00477035","phase":"PHASE1","title":"Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sally Arai","startDate":"2006-05","conditions":"Leukemia, Multiple Myeloma","enrollment":22},{"nctId":"NCT02886897","phase":"PHASE1, PHASE2","title":"A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-07","conditions":"Hepatocellular Carcinoma, Renal Cell Carcinoma, Bladder Cancer","enrollment":50},{"nctId":"NCT02539017","phase":"PHASE2","title":"The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2015-11","conditions":"Triple Negative Breast Neoplasms","enrollment":""},{"nctId":"NCT02418481","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02425735","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Liver Cancer","enrollment":40},{"nctId":"NCT02215837","phase":"PHASE2","title":"Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-08","conditions":"Gastric Cancer, Neoplasms, Gastrointestinal Neoplasms","enrollment":40},{"nctId":"NCT02487017","phase":"PHASE2","title":"DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2015-05","conditions":"Hepatocellular Carcinoma, Neoplasms, Digestive System Neoplasms","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CIK","CIK cells","DC-CIK and CIK","cytokine induced killer cells"],"phase":"phase_3","status":"active","brandName":"Cytokine-Induced Killer Cells","genericName":"Cytokine-Induced Killer Cells","companyName":"The First People's Hospital of Changzhou","companyId":"the-first-people-s-hospital-of-changzhou","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cytokine-Induced Killer (CIK) cells are ex vivo expanded autologous T lymphocytes that recognize and kill tumor cells through both MHC-restricted and non-restricted pathways. Used for Advanced solid tumors (phase 3 development), Hematologic malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}